Project Grant K99CA293148
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$147K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) provides $680,334 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the fundamental biological mechanisms underlying age-associated pathogenic myelopoiesis and its contribution to increased cancer risk and progression in aging populations. The 5-year study will utilize high-dimensional profiling, multi-omics phenotyping, and complex bone marrow experiments to...
This Project Grant award, with a total funding amount of $237,023, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research Federal Grant Program (CFDA 93.396). The award supports the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that can jointly capture gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. The goal is to gain unprecedented insights...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This Project Grant award, with a total funding amount of $689,914, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395). The award aims to delineate the mechanisms by which the concurrent loss-of-function mutations in the STK11 and KEAP1 genes confer resistance to ferroptosis-mediated cell death in aggressive subtypes of non-small cell lung cancer (NSCLC). The research will define the molecular and immune features...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the Icahn School of Medicine at Mount Sinai provides $701,330 to develop selective inhibitors targeting the lysine methyltransferase SETD8 for the treatment of multiple myeloma. The project aims to optimize SETD8 inhibitors discovered in preliminary studies into in vivo chemical probes and evaluate their efficacy in multiple myeloma cellular and mouse models. The goal is to further validate the...
This federal Project Grant award of $633,750.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, aimed at understanding the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This 3-year research project, from August 1, 2025 to July 31, 2028, seeks to...
This federal Project Grant award of $532,970.00, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The 5-year project, awarded to the Icahn School of Medicine at Mount Sinai, aims to study the transcriptional programs and secreted factors in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $441,178 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at overcoming therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. The key objectives are to: Investigate the cellular and developmental dependency of NUP98-NSD1-mediated leukemic initiation across different hematopoietic stem cell populations. Characterize the...